Lysosomal phospholipase A2 (LPLA2) activity as a therapeutic target for treating systemic lupus erythematosus
AssigneeThe Regents of the University of Michigan
InventorsJames A. Shayman, Akira Abe, Robert Kelly, Jessica Kollmeyer, Ye Lu
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.
Claims20
A method of treating a patient diagnosed with an autoimmune disorder having the symptom of accumulation of tingible body macrophages comprising:
- administering to said patient an effective amount of an agent,
- wherein the disorder is selected from the group consisting of systemic lupus erythematosus, drug-induced lupus, neonatal lupus, cutaneous lupus, and rheumatoid arthritis,
- wherein the agent comprises a peptide comprising an amino acid sequence selected from the group consisting of:
- (a) an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:
- 1;
- (b) N-terminal truncations of (a);
- and
- (c) C-terminal truncations of (a) or (b);
- and wherein the agent has LPLA2 enzymatic activity.
A method of treating a patient diagnosed with lupus erythematosus, drug-induced lupus, neonatal lupus, cutaneous lupus, or rheumatoid arthritis, the method comprising:
- administering to said patient an effective amount of an agent that has LPLA2 enzymatic activity and that comprises a peptide comprising an amino acid sequence selected from the group consisting of:
- (a) enzymatically active human LPLA2 having an amino acid sequence of SEQ ID NO:
- 1;
- (b) variants of (a) that differ from (a) at 15 or fewer amino acid residues;
- (c) N-terminal truncations of (a) or (b);
- and
- (d) C- terminal truncations of (a) - (c).
Dependencies are inferred from the claim text.